Дулоксетин Канон

Quick links

Choose a section

Quick links to important sections

Advertisements

Дулоксетин Канон

Advertisements

Overview of Дулоксетин Канон

Property Description
Active ingredient Duloxetine hydrochloride
Form Hard gastro-resistant capsule (Delayed-release capsule)
Pharmacological class Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
General purpose Mood stabilization and modulation of chronic pain signals
Origin Synthetic compound

Дулоксетин Канон: What Type of Medicine is It?

Дулоксетин Канон is a synthetic, prescription-only pharmaceutical preparation whose active ingredient is duloxetine. It is classified as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI), defining its function as a centrally acting drug within the therapeutic groups of both antidepressants and anxiolytics. Its general purpose, clinically recognized for effectiveness in central nervous system regulation, involves influencing chemical signaling to support emotional stability and aid in the processing of chronic pain signals.

What is the Composition and Form of Дулоксетин Канон?

The product is a single active ingredient product, containing duloxetine hydrochloride, and is designed for oral administration. It is supplied as a hard gastro-resistant capsule (delayed-release capsule), which is a key physical attribute and is distinct from standard immediate-release forms. The specific capsule formulation of Дулоксетин Канон is essential because the duloxetine molecule is known to be highly sensitive to the acidic environment of the stomach. This gastro-resistant matrix ensures the active substance is protected, allowing for reliable and predictable absorption later in the intestines, which is necessary for consistent therapeutic action.

The Dual-Action Principle: How Duloxetine Differs

The mechanism of duloxetine is defined by its dual-action principle: the potent inhibition of the neuronal reuptake of both serotonin and norepinephrine (noradrenaline). This dual regulatory effect provides a differentiating factor, setting it apart from classes of medications that only enhance a single neurotransmitter. Duloxetine affects the nervous system by increasing the concentrations of these critical neurotransmitters in the synaptic cleft. This dual regulatory effect provides a broader therapeutic benefit in supporting both emotional processing and the body’s management of persistent pain signals.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Дулоксетин Канон?

Possible side effects and safety information

The safety profile for duloxetine, the active ingredient in Дулоксетин Канон, is officially documented by regulatory authorities, classifying possible effects by their frequency and the body system affected. These classifications reflect how regulatory bodies organize and communicate the medicine’s risks.

Very Common Adverse Reactions (occurring in 10% or more of patients) primarily include nausea and headache.

Common Adverse Reactions (occurring in 1% to less than 10% of patients) involve effects across several systems, including Gastrointestinal Disorders (such as dry mouth, constipation, diarrhea, and vomiting) and Nervous System Disorders (such as dizziness, somnolence, and insomnia). Other common effects include hyperhidrosis (excessive sweating), fatigue, decreased appetite, and increased blood pressure.


Serious Adverse Reactions and Constraints

The official labeling highlights rare but clinically significant adverse reactions, including Serotonin Syndrome, which can occur especially when combined with other serotonergic agents, and the potential for Hepatotoxicity (severe liver injury). There is also a requirement to monitor for the emergence of Suicidal Thoughts and Behaviours, particularly at the initiation of therapy or following dose changes, especially in young adults.

Specific limitations on use are documented for certain populations. The medicine is generally contraindicated in individuals with severe hepatic impairment and in those with severe renal impairment (end-stage renal disease). Additionally, its use is restricted in patients with uncontrolled narrow-angle glaucoma and is prohibited alongside non-selective, irreversible Monoamine Oxidase Inhibitors (MAOIs).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with duloxetine is officially documented to present with several distinct clinical manifestations. These may include central nervous system depression, evidenced by somnolence, seizures, and potentially progressing to coma. Documented physiological signs also include tachycardia, hypertension, and vomiting. The presence of symptoms consistent with Serotonin Syndrome is of critical concern, as this is a severe, life-threatening event requiring specific intervention.

In the event of a suspected overdose, immediate medical care must be sought, especially if manifestations such as agitation, confusion, or severe fluctuations in vital signs occur. According to official regulatory labeling, no specific antidote is known for duloxetine. Therefore, clinical management relies entirely on symptomatic and supportive treatment.

Official procedures described for managing acute overdose situations include continuous monitoring of vital signs and cardiac function, and ensuring a patent airway. Decontamination measures such as the administration of activated charcoal or consideration of gastric lavage may be utilized to limit systemic exposure. Furthermore, patients with documented severe renal impairment or chronic liver disease are noted in official labeling to be at an elevated risk for drug accumulation and resultant toxicity following overdose.

Advertisements

Therapeutic Uses of Дулоксетин Канон

The primary therapeutic utility of this medication is centered on addressing significant emotional distress and certain pervasive chronic pain syndromes, as commonly recognized in the clinical domain, which focuses on symptomatic management across several challenging clinical domains.


Relief for Dual Symptom Domains

This medication is used in the treatment of Major Depressive Disorder and is applied in addressing the symptoms of Generalized Anxiety Disorder (GAD). It helps manage groups of symptoms that involve persistently low mood and excessive worry, which may assist with emotional regulation and supports general well-being during symptomatic phases. It is also commonly used for managing symptoms related to increased neurological or muscular activity, specifically the long-term, nerve-related pain of diabetic peripheral neuropathic pain, the widespread body aching of Fibromyalgia, chronic low back pain, and pain related to osteoarthritis.


Therapeutic Benefit

It helps address symptom clusters that may become intense or disruptive, and is applied in addressing challenging symptoms that create noticeable functional strain. This provides supportive relief when symptoms interfere with routine activities and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Chronic Symptom Management

  • This medication is considered relevant for easing persistent pain sensations like burning, tingling, and numbness, which are symptomatic manifestations of increased neurological or muscular activity.
  • It is commonly used to help with groups of symptoms that involve emotional distress and symptoms related to physical discomfort.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility for Дулоксетин Канон

Official regulatory documents define strict criteria for the use of duloxetine, based on age, organ function, and concurrent treatment. The medicine is primarily indicated for adults (18 years and older) across all approved conditions, though eligibility extends to certain pediatric groups: it is established for Generalized Anxiety Disorder (GAD) starting at 7 years and for Fibromyalgia starting at 13 years.

Eligibility Status Key Restriction or Contraindication
Absolutely Contraindicated Severe renal impairment (CrCl <30 mL/min), hepatic impairment (liver disease), uncontrolled hypertension, or concomitant use with MAOIs or potent CYP1A2 inhibitors (e.g., fluvoxamine).
Not Recommended Children and adolescents under 18 for Major Depressive Disorder. Use during breastfeeding. Avoidance is advised for patients with substantial alcohol use.
Conditional Use Use in the third trimester of pregnancy requires caution due to risk of neonatal symptoms. Caution is also advised for patients with controlled narrow-angle glaucoma.

The safety and efficacy of the medicine are not established for GAD in children under 7 years or for Fibromyalgia in children under 13 years. For the elderly, no dosage adjustment is required based solely on age, but caution is recommended.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information classifies several drug and substance combinations with Дулоксетин Канон (duloxetine) as restricted or contraindicated based on pharmacokinetic and pharmacodynamic patterns.

Contraindicated and Restricted Combinations

Classification Interacting Agents Rationale in Official Documents
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Risk of severe Serotonin Syndrome; requires mandatory 14-day separation.
Contraindicated Potent CYP1A2 Inhibitors (e.g., Fluvoxamine, Ciprofloxacin) Significantly increases duloxetine plasma concentrations and exposure (AUC).
Contraindicated Thioridazine Increased thioridazine concentration due to CYP2D6 inhibition by duloxetine, risking serious cardiac arrhythmias.

Other Clinically Significant Interactions

Duloxetine is a moderate inhibitor of the CYP2D6 enzyme. Co-administration with other drugs metabolized primarily by CYP2D6 (e.g., certain TCAs) may result in an increase in the plasma concentration of the co-administered drug. The combination with other serotonergic agents (including triptans and other SNRIs) carries a documented risk of additive pharmacodynamic effects.

Furthermore, concomitant use with antiplatelet agents or oral anticoagulants is officially noted to increase the risk of bleeding events. Regulatory information also advises caution regarding co-administration with alcohol, citing an increased risk of severe hepatotoxicity. Usage is to be avoided in patients with severe hepatic or renal impairment (e.g., GFR < 30 mL/minute) as clearance is reduced, which amplifies the risk of interactions and exposure.

Advertisements

Mechanism of Action

How Дулоксетин Канон Works: Mechanism of Action

Дулоксетин Канон functions by inhibiting two key presynaptic proteins in the central nervous system: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). This dual inhibition prevents the reuptake of the neurotransmitters serotonin (5-HT) and norepinephrine (NE), leading to a prolonged and elevated concentration of both chemical messengers within the synaptic cleft.

This increased availability of 5-HT and NE in the spinal cord enhances the activity of the descending pain inhibitory pathway (DPIP). This pathway is involved in the central suppression of nociceptive signal transmission. The drug's influence on these systems modulates the regulation of sensory and emotional stimuli transmission, adjusting the balance of central signal processing. Duloxetine exhibits high specificity for SERT and NET, and this selective pathway focus influences the steady state of neural activity in targeted circuits.

Advertisements

Dosage and Administration Information

How to Use Duloxetine (Дулоксетин Канон) — Official Administration Guidelines

Administration of duloxetine is strictly defined by official labeling, ensuring the drug's properties are preserved for proper therapeutic action. The medicine is supplied as a delayed-release, hard gastro-resistant capsule and is intended exclusively for oral administration. The capsule must be swallowed whole and must not be crushed, chewed, or opened, as doing so would compromise the protective coating essential for absorption.

Dosing Regimens and Frequency

Use typically follows a structured sequence. For many approved adult indications, dosing starts with a lower dose, such as 30 mg once daily for one week, before increasing to the standard maintenance dose of 60 mg once daily. This titration phase establishes a standardized protocol for starting therapy. The overall schedule is usually once daily, although maximum dosages (up to 120 mg per day) may require administration in divided doses. The medicine may be taken with or without food.

Procedural Constraints and Special Populations

Adherence to the schedule requires a specific rule for handling timing errors: if a dose is missed, it should be taken as soon as remembered, but never take two doses simultaneously. Furthermore, the official protocol includes specific use-context constraints: duloxetine is officially not recommended for use in patients with severe renal impairment or those with hepatic impairment, as these conditions structurally impact the drug's approved use.

Advertisements

Recent Clinical Evidence

Duloxetine Canon: Recent Clinical Evidence

Recent clinical research on Duloxetine (the active ingredient in Duloxetine Canon) has focused on its utility across multiple conditions, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and various chronic pain syndromes.

Efficacy and Outcomes

Clinical trials, including randomized, placebo-controlled studies and meta-analyses, have investigated the effects of duloxetine on symptom severity and quality of life. Key findings frequently highlight:

  • Depressive Symptoms: Studies consistently examine reductions in depressive symptom scores when compared to placebo in the short term (6 to 16 weeks). The magnitude of the observed change is generally considered minimal to small but statistically significant.
  • Pain Syndromes: Duloxetine has been studied for its role in conditions such as diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Research evaluated whether the drug affected 24-hour average pain severity scores versus placebo. For patients with MDD who also experience painful physical symptoms, studies have investigated a concurrent effect on both types of symptoms.

Tolerability and Safety Profile

The assessment of tolerability is a major component of the clinical data. In a pooled analysis of safety data from multiple trials across various indications, the overall tolerability profile was generally favorable.

Common Treatment-Emergent Events
Nausea, dry mouth, somnolence, fatigue, dizziness, and constipation.

Discontinuation rates due to adverse events are typically higher in the duloxetine group compared to the placebo group. The effects of the medication on risks of serious adverse events or suicidality over the short- and long-term remain uncertain and require ongoing systematic assessment. Specific patient populations, such as those with severe liver disease or uncontrolled narrow-angle glaucoma, were excluded from clinical trials due to contraindications.

Key Studies & References

  1. Duloxetine in the management of chronic low back pain: a randomized, double-blind, placebo-controlled trial
  2. NICE Guideline NG222: Depression in adults: treatment and management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Дулоксетин Канон (FAQ)


Q: How long does it usually take for Duloxetine Canon to start working?

Official sources indicate that a patient may need to take the medication for several weeks before experiencing its full therapeutic effect. It is important to continue using the medication as prescribed, even if a noticeable improvement is not immediately apparent.


Q: Is Duloxetine Canon considered a strong medication?

Regulatory documents classify the medication as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). Its action is defined by its influence on two key neurotransmitters in the central nervous system. Official sources do not use subjective evaluative terms like 'strong' to describe its therapeutic classification.


Q: Is Duloxetine Canon addictive or does it cause dependence?

Duloxetine is generally not classified as a controlled substance by regulatory agencies and is considered to have a very low potential for misuse. However, official product information indicates that symptoms may occur if the medicine is stopped, a concept known as discontinuation symptoms.


Q: Can I stop taking Duloxetine Canon abruptly?

Official instructions do not recommend stopping the medication abruptly. Instead, regulatory documents recommend that treatment be ended with a gradual dose reduction process. This procedure helps minimize the potential for developing discontinuation symptoms.


Q: Does Duloxetine Canon affect body weight (loss or gain)?

In short-term controlled clinical trials, patients taking duloxetine generally experienced a small average weight loss compared to those taking placebo. The effect on weight is considered a possible side effect, with observed changes generally being small.


Q: How long do I typically need to take Duloxetine Canon?

The prescribing information indicates that the overall duration of use is subject to a medical professional's periodic assessment. Official regulatory documents indicate that the efficacy of the medication for long-term use (more than 9 weeks) has not been systematically evaluated in controlled trials.


Q: Do I need blood tests or lab work before starting Duloxetine Canon?

Since the medication is officially contraindicated in cases of severe liver or kidney impairment, official documents assume a baseline evaluation of these functions will be performed prior to use. This assessment ensures proper patient eligibility, and additional testing (e.g., sodium or glucose) may be relevant depending on the patient’s profile.


Q: What should I do if I miss a dose of Duloxetine Canon?

Official labeling describes the procedure for a missed dose as taking it as soon as it is remembered, with the critical constraint that two doses must never be taken at the same time. You should then resume the regular dosing schedule.


Q: Are there special instructions for using Duloxetine Canon in older adults?

Dose adjustment based solely on age is not required according to regulatory documents. However, caution is advised because older patients may be more susceptible to certain side effects, such as dizziness or low sodium levels (hyponatremia).


Q: What is the maximum amount of the drug that can be taken?

The maximum dosage listed in the official prescribing information for most approved conditions is 120 mg per day. However, it is noted that for some specific indications, doses higher than 60 mg per day have not consistently shown additional therapeutic benefit.


Q: Can Duloxetine Canon be taken during pregnancy or breastfeeding?

Use during the third trimester of pregnancy requires caution due to a documented risk of neonatal symptoms, such as breathing difficulties, in the newborn. While the use during the first and second trimesters is not associated with clear, confirmed risks in observational studies, use during breastfeeding is officially not recommended.


Q: Can Duloxetine Canon cause anxiety or agitation initially?

Official documents note that anxiety and irritability can occur, particularly when treatment is first started or following a change in dosage. These are listed as potential adverse reactions, and anxiety is also a known symptom associated with the gradual reduction of the dose.


Q: Can Duloxetine Canon affect sexual function?

Yes, official regulatory information indicates that this medication can be associated with sexual side effects. These may include decreased libido (sex drive), delayed or impaired orgasm, and erectile dysfunction in men. The labeling notes that prescribers should regularly inquire about the emergence of these side effects.


Q: Does Duloxetine Canon relieve chronic pain?

The drug is officially approved by regulatory bodies to manage certain types of chronic pain. This includes diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (such as chronic low back pain or pain from osteoarthritis). Its mechanism of action involves the modulation of central pain signals.


Q: How does Duloxetine Canon affect blood sugar levels?

Official data indicates that patients with diabetes taking duloxetine have shown a small increase in blood glucose levels and glycated hemoglobin (HbA1c). The official documentation includes a recommendation for periodic blood sugar monitoring for patients with diabetes.


Q: Can Duloxetine Canon cause urinary problems?

Official sources indicate that the medication may potentially cause difficulty urinating (dysuria). In rare cases, more severe symptoms such as urinary retention, where a person cannot completely empty the bladder, have also been noted.


Q: Are there restrictions on caffeine consumption with Duloxetine Canon?

While there are no explicit contraindications against caffeine consumption in official documents, the medication’s interaction profile with liver enzymes suggests caution. Since high caffeine intake can cause restlessness and insomnia, excessive consumption may increase the experience of side effects that are already associated with duloxetine, such as insomnia.


Q: Is Duloxetine Canon a controlled or narcotic substance?

Duloxetine is not classified as a controlled substance or narcotic under major regulatory frameworks. This classification indicates that the drug has a low potential for abuse or dependence.


Q: Are there studies on the long-term use of Duloxetine Canon?

Regulatory documents note that the medication's effectiveness during long-term use (beyond nine weeks) for treating conditions like major depressive disorder has not been systematically evaluated in placebo-controlled trials. Physicians are expected to periodically assess the necessity of continued long-term therapy.


Q: Does Duloxetine Canon help with Generalized Anxiety Disorder?

Yes, the medication is officially approved and indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults. It is also approved for this condition in pediatric patients aged 7 to 17 years.


Q: Do I need to change my diet when taking Duloxetine Canon?

The medication can be taken with or without food, and official documents do not require any specific dietary changes for its use. However, caution regarding alcohol intake is officially advised.


Q: Is the effectiveness of Duloxetine Canon related to the dosage?

Official data suggests that for some indications, there is no clear evidence that doses higher than 60 mg per day provide additional therapeutic benefit, though these higher doses may increase the frequency of side effects. Initial lower doses are often used to improve tolerability during the start of therapy.


Q: What is the difference between Duloxetine Canon and other duloxetine products?

Duloxetine Canon contains the exact same active pharmaceutical ingredient (duloxetine hydrochloride) as other products containing duloxetine. Any differences between brand names and generics typically relate only to non-active ingredients (excipients) or the manufacturer. All regulatory-approved products must meet the same quality and efficacy standards.


Q: Does Duloxetine Canon have a sleep-inducing effect?

The medication is listed as potentially causing both somnolence (drowsiness) and insomnia (sleeplessness). Somnolence, along with other central nervous system effects, is listed as one of the common adverse reactions, especially at the beginning of treatment.

Advertisements

How should Дулоксетин Канон be stored and disposed of?

How to Store and Dispose of Duloxetine

Official labeling defines strict requirements to protect the integrity of the gastro-resistant capsules and maintain the product's stability.

Storage Requirements

Storage Component Regulatory Mandate
Temperature Store at a temperature not exceeding 25 C.
Environment Must be stored in a dry place and protected from light.
Packaging Keep the medicine in its original packaging (blister in the pack).
Shelf Life Do not use the product after the expiration date; shelf life is 3 years.

Safety and Disposal

All medicine must be stored out of the sight and reach of children.

Disposal of unused or expired Duloxetine and waste materials must be performed strictly in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дулоксетин Канон found in:

A-Z Index: